{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:32:13Z","timestamp":1793291533952,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["29542"],"award-info":[{"award-number":["29542"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.esmoop.2026.108596","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:15:05Z","timestamp":1791850505000},"page":"108596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cOur patients deserve better\u201d\u2014roadblocks to optimal care in biliary malignancies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"A.","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2093-3316","authenticated-orcid":false,"given":"I.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4440-9583","authenticated-orcid":false,"given":"M.I.","family":"Crespo Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-4694","authenticated-orcid":false,"given":"A.","family":"Cammarota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1604","authenticated-orcid":false,"given":"J.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108596_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2026.108596_bib2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmoop.2026.108596_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.108596_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.4251\/wjgo.v15.i12.2077","article-title":"Cohort study to assess geographical variation in cholangiocarcinoma treatment in England","volume":"15","author":"Jose","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib6","article-title":"Cholangiocarcinoma across England: temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation","volume":"6","author":"Tataru","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.esmoop.2026.108596_bib7","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3748\/wjg.v29.i24.3825","article-title":"Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017","volume":"29","author":"Zalin-Miller","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmoop.2026.108596_bib8","article-title":"Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: a nationwide retrospective analysis","volume":"15","author":"Neuzillet","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.esmoop.2026.108596_bib9","series-title":"Proceedings of the Cholangiocarcinoma Foundation 12th Annual Conference","article-title":"The challenge of diagnosing biliary tumours: an unmet need","author":"Lamarca","year":"2025"},{"key":"10.1016\/j.esmoop.2026.108596_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106306","article-title":"Phase III trial of infigratinib versus gemcitabine\/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301","volume":"11","author":"Abou-Alfa","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108596_bib11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO-26-00788","article-title":"Pemigatinib for unresectable or metastatic cholangiocarcinoma with fibroblast growth factor receptor-2 rearrangement: results from the phase III FIGHT-302 trial","volume":"44","author":"Bekaii-Saab","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.108596_bib12","article-title":"326P The journey of patients (pts) with biliary tract cancers (BTCs): identifying challenges and unmet needs","volume":"36","author":"Corallo","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib22","doi-asserted-by":"crossref","first-page":"100409","DOI":"10.1016\/j.esmogo.2026.100409","article-title":"Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study","volume":"14","author":"Martirena","year":"2026","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib13","article-title":"Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: a systematic review and meta-analysis","volume":"8","author":"Akkus","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.esmoop.2026.108596_bib14","article-title":"Mapping the landscape of biliary tract cancer in Europe: challenges and controversies","volume":"50","author":"Rimassa","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108596_bib15","first-page":"LBA100","article-title":"NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening","volume":"44","author":"Swanton","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib16","series-title":"Ziihera (zanidatamab): EPAR","year":"2025"},{"key":"10.1016\/j.esmoop.2026.108596_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cjp2.308","article-title":"First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma","volume":"9","author":"Neumann","year":"2023","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.esmoop.2026.108596_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.annonc.2024.01.001","article-title":"Improved nationwide survival of sarcoma patients with a network of reference centers","volume":"35","author":"Blay","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108596_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ejso.2021.10.031","article-title":"Centralisation of rectal cancer care has improved patient survival in the Republic of Ireland","volume":"48","author":"O\u2019Connell","year":"2022","journal-title":"Eur J Surg Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602541X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602541X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:41:19Z","timestamp":1793288479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602541X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S205970292602541X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108596","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cOur patients deserve better\u201d\u2014roadblocks to optimal care in biliary malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108596"}}